US 11155621
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
granted A61KA61K2039/505A61P
Quick answer
US patent 11155621 (Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00, A61P35/02